Human fibroblasts held in long-term post-mitotic culture reproduce the transcriptomic and epigenetic signatures of aging observed in tissue, on a compressed timescale, and retain their acquired biological age when directly converted into neurons. Applied as a screening platform, the system showed broad attenuation of molecular aging markers with metformin, while rapamycin produced limited effect. The approach allows candidate geroprotective compounds to be assessed in human cells before clinical testing.
Key Points
- Post-mitotic fibroblast culture accelerates authentic human molecular aging signatures
- Direct neuronal conversion preserves biological age for longitudinal modeling
- Metformin attenuated aging markers; rapamycin showed limited molecular efficacy
Longevity Analysis
Most claims about anti-aging compounds rest on animal models or indirect human biomarkers. A human-cell platform that compresses decades of molecular drift into months allows interventions to be judged against the actual transcriptional and epigenetic signatures that accompany declining regenerative capacity and tissue repair. The divergence between metformin and rapamycin here is a reminder that compounds with overlapping reputations act through distinct mechanisms, and that selecting among them requires molecular evidence rather than category assumptions. The increase in cell-to-cell heterogeneity over time also reinforces why chronological age predicts function poorly, and why individual measurement matters more than population averages.
Original published by Wiley Aging Cell, by Larissa Traxler, Lukas Karbacher, Oliver Borgogno, Taylor Ozbun, Kylie Champion, Anna Smaling, Lucia Zhou‐Yang, Joseph R. Herdy, Lena Böhnke, Barbara C. Böckle, Fred H. Gage, Hildegard I. D. Mack, Michaela Defrancesco, Jerome Mertens .